RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Conditions
- Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT
- Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
- DRUG: BCMA/CD19-targeted allogeneic CAR-T
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators